China offers alternative gateways for experimental drugs

Article Abstract:

Several experimental biological drugs pioneered by the Western biotech companies that failed to reach the US or European markets were approved in China. Some argue that China could prove a useful testing ground from which to launch experimental therapies into the West while others argue that it would take more than a flexible regulatory regime to start Chinese biotech startup activity or convince foreign biotech companies to carry out testing in China.

Product development, Government domestic functions, Government regulation, Science and technology policy, Licensing, certification and accreditation, Drug approval

---

China ramps up efforts to commercialize GM rice

Article Abstract:

A budget increases for research and field trails of genetically modified (GM) rice varieties since 2001 indicate that China is forging ahead with their commercialization. China's fear that it would not be able to produce enough rice to support its growing population may impel the country to become the first in the world to approve GM rice.

Management dynamics, Rice milling, Management, Economic policy, Rice, Company business management, Cereal products, Rice products, Genetically modified crops, Overpopulation

---

China moves to reform biotech policies

Article Abstract:

China reforms the biotech industry through creating top-level biotech leadership committee. Several government departments in China are drafting national plans in biotech sector to avoid duplication, but it will be effective only if the government introduces a better system to finance biotech research.

Government finance

Similar abstracts:

• Abstracts: Investor presentations. Investor relations services. Know your social media
• Abstracts: Chief integrity officer is tailor-made for PR. No 'quick fixes' to nation's public diplomacy woes. Don't be a casualty in the 'culture wars'
• Abstracts: Biotech buybacks: good or bad? Beware the biotech barker. Biotech IPOs-flop or pop?
• Abstracts: Europe caught in innovation quagmire. Antibodies' long revenue stream spurs pharma acquisitions. Sanofi takeover jeopardizes Aventis biotech deals

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.